Adjuvant InterFeron After Curative Resection of HCV-related Hepatocellular Carcinoma in Elderly Patients: a Multicenter Randomized Controlled Trial

INTERVENTION: Adjuvant interferon alpha therapy. Three times of 3,000,000 units / a week. Close follow‐up CONDITION: HCV‐related hepato cellular carcinoma PRIMARY OUTCOME: Recurence free survival INCLUSION CRITERIA: 1) Ages between 61 and 77 years old 2) Primary HCC or recurrent HCC more than two years after previous therapy 3) Classical HCC 4) HCV chronic hepatitis or cirrhosis 5) No extrahepatic lesions 6) Fine or moderate organ function fulfilling the following criteria. 7) Child‐Pugh score < 8 8) ECOG performance status 0‐2 9) CES‐D score <16 10) Written informed consent